DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

DVA·DaVita Inc.

$.
+. (+.%)
After Hours
High
$235.00
Open
$230.91
Market Cap
14.88B
52W High
$239.64
Low
$228.43
P. Close
$232.80
P/E
19.05
52W Low
$101.00
Fwd P/E
13.52
DailyIQ Est.
$198.56
Technical Score (1D)
86
BUY
News Sentiment
89
BULLISH
UBS has lifted its price target for DaVita to $270 from $235, citing an improved earnings outlook and stronger market positioning that should help the company navigate upcoming regulatory changes. The upgrade signals confidence that DaVita’s dialysis services will continue to grow, which could support a more favorable valuation in the near term. Traders should keep an eye on the company’s next earnings release for confirmation of the earnings trajectory and any updates on Medicare reimbursement rates that could validate the new target. In addition, the recent inclusion of DaVita in Berkshire Hathaway’s portfolio under Weschler’s stewardship has already driven a rally, suggesting that institutional backing may reinforce the company’s fundamentals. The fact that Berkshire is leaning on Weschler’s picks could mean further allocation to DaVita if the firm’s performance remains strong, potentially adding buying pressure. Monitoring Berkshire’s quarterly portfolio adjustments will provide early signals of any shift in institutional sentiment. The combination of a higher price target and institutional support underscores a bullish outlook for the next 1–10 trading days, but the market remains sensitive to Medicare policy changes. Watch for any regulatory announcements or Medicare rate adjustments that could alter the earnings outlook and, consequently, the valuation narrative.
Earnings Summary
DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating outpatient dialysis centers and offering inpatient, home‑based, and laboratory services as part of a comprehensive kidney‑care platform. The company’s business is anchored in the medical‑care‑facilities sector, where reimbursement dynamics and patient volume drive performance. In the most recent quarters, DaVita’s Q4 2024 earnings surpassed expectations with an EPS of $2.24 versus a $2.13 estimate and revenue of $3.295 billion, while Q1 2025 saw a modest EPS miss at $2.00 against a $2.02 estimate and revenue of $3.224 billion; Q2 2025 reversed the trend with an EPS of $2.95 beating a $2.75 estimate and revenue of $3.380 billion, but Q3 2025 recorded an EPS of $2.51 below a $3.17 estimate despite revenue of $3.420 billion; Q1 2026 again beat expectations with an EPS of $2.87 versus $2.33 and revenue of $3.416 billion versus a $3.356 billion estimate. Over the past year, revenue has fluctuated, rising from $3.295 billion in Q4 2024 to $3.420 billion in Q3 2025 before settling near $3.416 billion in Q1 2026, while EPS has oscillated between $2.00 and $2.95, indicating a pattern of earnings volatility amid steady revenue growth. Recent news highlights a Barclays price‑target upgrade to $218, a Zacks Rank #1 growth designation, and the rollout of AI‑driven scheduling tools that could enhance operational efficiency; these developments underscore market confidence in DaVita’s growth trajectory and potential margin improvement. Investors should watch for the Q2 2026 earnings release to confirm guidance, monitor regulatory updates that could affect Medicare reimbursement rates, and assess the pace of AI tool deployment, as these factors will be key to sustaining the company’s earnings momentum.

EPS

EstBeatMiss
$1.72$2.33$2.94$3.55$4.16Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.88 - -
Q1'26$2.33$2.87+23.2%
Q3'25$3.17$2.51-20.9%
Q2'25$2.75$2.95+7.3%
Q1'25$2.02$2.00-1.0%
Q4'24$2.13$2.24+5.4%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.4B$3.5BQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.5B - -
Q1'26$3.4B$3.4B+1.8%
Q3'25 - $3.4B -
Q2'25 - $3.4B -
Q1'25 - $3.2B -
Q4'24 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DVA Stock Snapshot

DVA is currently trading at $235.00, giving DaVita Inc. a market cap of 14.88B and a P/E ratio of 19.1. Today's range spans $228.43–$235.00, with shares opening at $230.91 and moving up $2.20 (0.9%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 89/100.

Over the past year DVA has traded between $101.00 and $239.64 - the current price is +132.7% off the 52-week low and -1.9% from the high. 14 analysts cover the stock with a Hold consensus and a mean 12-month target of $197.14 (range $145.00–$235.00), implying downside of -16.1%.

DaVita Inc. (DVA) is a large-cap in Healthcare with 14.88B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 86/100 (BUY). Sentiment: bullish at 89/100. Price: $235.00 (near 52-week highs). The current P/E ratio stands at 19.1. The 52-week range of $101.00–$239.64 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (89/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $235.00 (near 52-week highs), DVA's position within the $101.00–$239.64 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.